Rhythm Pharmaceuticals (RYTM) Competitors $65.14 -1.25 (-1.88%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$63.68 -1.46 (-2.23%) As of 08:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RYTM vs. ITCI, GMAB, RDY, MRNA, RGC, VTRS, QGEN, ASND, BBIO, and BPMCShould you be buying Rhythm Pharmaceuticals stock or one of its competitors? The main competitors of Rhythm Pharmaceuticals include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Regencell Bioscience (RGC), Viatris (VTRS), QIAGEN (QGEN), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Rhythm Pharmaceuticals vs. Its Competitors Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Moderna Regencell Bioscience Viatris QIAGEN Ascendis Pharma A/S BridgeBio Pharma Blueprint Medicines Intra-Cellular Therapies (NASDAQ:ITCI) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment. Which has better earnings and valuation, ITCI or RYTM? Intra-Cellular Therapies has higher revenue and earnings than Rhythm Pharmaceuticals. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64Rhythm Pharmaceuticals$130.13M31.85-$260.60M-$2.81-23.18 Does the media refer more to ITCI or RYTM? In the previous week, Rhythm Pharmaceuticals had 12 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 13 mentions for Rhythm Pharmaceuticals and 1 mentions for Intra-Cellular Therapies. Rhythm Pharmaceuticals' average media sentiment score of 0.55 beat Intra-Cellular Therapies' score of 0.00 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intra-Cellular Therapies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rhythm Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of ITCI or RYTM? 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 2.6% of Intra-Cellular Therapies shares are held by insiders. Comparatively, 6.1% of Rhythm Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is ITCI or RYTM more profitable? Intra-Cellular Therapies has a net margin of -14.07% compared to Rhythm Pharmaceuticals' net margin of -123.26%. Intra-Cellular Therapies' return on equity of -9.93% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% Rhythm Pharmaceuticals -123.26%-739.62%-44.27% Do analysts rate ITCI or RYTM? Intra-Cellular Therapies presently has a consensus target price of $109.70, suggesting a potential downside of 16.81%. Rhythm Pharmaceuticals has a consensus target price of $78.07, suggesting a potential upside of 19.85%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Rhythm Pharmaceuticals is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17Rhythm Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, ITCI or RYTM? Intra-Cellular Therapies has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.26, meaning that its stock price is 126% more volatile than the S&P 500. SummaryRhythm Pharmaceuticals beats Intra-Cellular Therapies on 9 of the 16 factors compared between the two stocks. Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RYTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RYTM vs. The Competition Export to ExcelMetricRhythm PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.22B$2.87B$5.50B$8.95BDividend YieldN/A2.45%5.25%4.04%P/E Ratio-23.1820.8026.9720.11Price / Sales31.85286.31425.92119.81Price / CashN/A41.1936.8257.86Price / Book186.117.487.985.56Net Income-$260.60M-$55.04M$3.16B$248.40M7 Day Performance-2.66%2.44%2.36%4.67%1 Month Performance-2.37%1.90%2.15%6.64%1 Year Performance44.95%4.35%33.78%21.31% Rhythm Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RYTMRhythm Pharmaceuticals4.006 of 5 stars$65.14-1.9%$78.07+19.9%+48.9%$4.22B$130.13M-23.18140News CoverageAnalyst ForecastITCIIntra-Cellular Therapies0.7316 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560News CoverageGMABGenmab A/S4.0088 of 5 stars$20.52+1.1%$37.60+83.2%-16.6%$13.02B$3.12B11.662,682News CoverageAnalyst ForecastRDYDr. Reddy's Laboratories2.709 of 5 stars$15.08flat$16.95+12.4%-4.7%$12.59B$325.54B22.8527,811MRNAModerna4.3741 of 5 stars$29.90-1.9%$46.61+55.9%-72.1%$11.79B$3.24B-3.425,800Gap UpRGCRegencell Bioscience0.3808 of 5 stars$18.43-19.8%N/AN/A$11.37BN/A0.0010Gap UpHigh Trading VolumeVTRSViatris2.6668 of 5 stars$9.20-1.3%$10.40+13.0%-12.7%$10.94B$14.74B-2.9032,000QGENQIAGEN3.8865 of 5 stars$47.49-1.8%$49.40+4.0%+22.3%$10.75B$1.98B119.075,765ASNDAscendis Pharma A/S3.4843 of 5 stars$175.98+1.0%$220.67+25.4%+23.2%$10.65B$393.54M-28.021,017BBIOBridgeBio Pharma4.6672 of 5 stars$43.50-1.1%$58.85+35.3%+65.2%$8.35B$221.90M-12.32400BPMCBlueprint Medicines1.5056 of 5 stars$128.40+0.0%$128.06-0.3%+10.4%$8.29B$508.82M-51.98640News CoverageInsider Trade Related Companies and Tools Related Companies Intra-Cellular Therapies Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Moderna Competitors Regencell Bioscience Competitors Viatris Competitors QIAGEN Competitors Ascendis Pharma A/S Competitors BridgeBio Pharma Competitors Blueprint Medicines Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RYTM) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RYTM Stock Alerts